Cambridge, UK, 08 July 2025: Dr Jordan Lane, Chief Scientific Officer at Ignota Labs, has been appointed Industry and Enterprise Fellow of Clare Hall, Cambridge, for his extensive experience in the AI drug discovery space.
Earlier this year, Clare Hall announced the creation of this new category of senior membership for individuals with an established research or commercial track record, particularly in tech or biotech. Dr Lane joins Dr Keith Dear, CEO and founder of Cassi; Dr Jiahao Huang, co-founder of Nuclera; Dr Loukik Arora, Impact Investment Lead at Macmillan; and Dr Quentin Harmer, CTO of Endomag, as the first people appointed to this new Fellowship.
Despite being the smallest college by student number, Clare Hall is home to the largest Visiting Fellowship programme, with around 40 visiting senior academics in residence each year, as well as 24 Research Fellows, and senior members from varying professions beyond academia. The result is a diverse and close-knit international community with a focus on research.
Dr Lane leads innovation at Ignota Labs, leveraging his extensive background in drug discovery and AI to pioneer transformative treatments in global patient care. He is driven by a profound commitment to revolutionising drug discovery, integrating artificial intelligence with bioscience to enhance drug safety and efficacy.
Dr Jordan Lane, CSO of Ignota Labs, said: “Cambridge’s innovation ecosystem thrives on cross-disciplinary collaboration and intellectually stimulating engagement with a diverse range of people. It is an honour for me to be appointed to this Fellowship and I look forward to working with the extraordinary community at Clare Hall.”
Since announcing a seed raise of £5.5M earlier this year, Ignota Labs has in-licensed multiple drugs, doubled the size of its team, and entered into a collaboration with global healthcare company Sanofi.
About Ignota Labs
Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering $400 billion annual loss and delaying life-saving treatments for patients. Our proprietary platform, SAFEPATH, uses cutting-edge deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Unlike traditional safety assessments that identify what went wrong, our AI platform SAFEPATH combines cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates. Ignota Labs is building a robust pipeline to bring safer drugs to market faster, partnering to develop and co-develop
Media Contact
Hailey Eustace
hailey@commplicated.com
+44 (0)7872 629 960
